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Abstract: Variants of NR5A1 are often found in individuals with 46,XY disorders of sex development
(DSD) and manifest with a very broad spectrum of clinical characteristics and variable sex hormone
levels. Such complex phenotypic expression can be due to the inheritance of additional genetic
hits in DSD-associated genes that modify sex determination, differentiation and organ function in
patients with heterozygous NR5A1 variants. Here we describe the clinical, biochemical and genetic
features of a series of seven patients harboring monoallelic variants in the NR5A1 gene. We tested the
transactivation activity of novel NR5A1 variants. We additionally included six of these patients in
a targeted diagnostic gene panel for DSD and identified a second genetic hit in known DSD-causing
genes STAR, AMH and ZFPM2/FOG2 in three individuals. Our study increases the number of NR5A1
variants related to 46,XY DSD and supports the hypothesis that a digenic mode of inheritance may
contribute towards the broad spectrum of phenotypes observed in individuals with a heterozygous
NR5A1 variation.
Keywords: disorder/difference of sex development; DSD; steroidogenic factor 1; NR5A1/SF1; STAR;
AMH; FOG2; oligogenic disorders; genotype–phenotype correlation
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1. Introduction
Sex development depends on a tightly controlled network of transcription factors and signaling
pathways working in concert to produce functional gonads and typical sex organs. Variations in this
complex development lead to disorders/differences of sex development (DSD), which may manifest
with a broad spectrum of clinical conditions [1]. The NR5A1 gene, also known as the steroidogenic
factor 1 (SF1) gene, is suggested as causative in 10–20% of 46,XY DSD [2]. A human variation in NR5A1
was first detected in a 46,XY DSD individual with complete gonadal dysgenesis combined with adrenal
insufficiency [3], and was mimicking the phenotype of the Sf1 knockout (KO) mouse [4]. Later studies
revealed that an adrenal phenotype is rarely found in patients with NR5A1 variants [5], and that the
gonadal and reproductive phenotype may be very broad including 46,XY and 46,XX cases [6]. Variable
gonadotropins, sex hormones and anti-Müllerian hormone (AMH) levels are also found in patients
with NR5A1 variants, as well as inconsistent findings regarding gonadal histology [2].
NR5A1 disease-causing variants are detected throughout the whole gene and they are mostly
found in a heterozygous state. The pathogenic effect of NR5A1 variants has been widely shown in
clinical studies, however mechanistic proof through in vitro studies remains inconclusive. Transient
in vitro transactivation assays of NR5A1 regulated genes did not show a functional impact of
several variants, and a dominant negative effect for heterozygous variants was also not found [7].
In fact, haploinsufficiency seems to be insufficient to explain the complex phenotypic expression,
as individuals with the same genetic variation may present with different clinical characteristics,
even within the same family [8]. Given the highly varying phenotype and incomplete penetrance,
a direct genotype–phenotype correlation is missing and needs further explanation [9]. Additional
gene variants as disease modulators or environmental factors have been suggested [8]. Recently,
Mazen et al. identified a second MAP3K1 gene variant in a 46,XY DSD patient heterozygous for
NR5A1 [10]. Meanwhile several other patients have been reported carrying oligogenic NR5A1 variants
in combination with other variants in DSD-related genes [2,8,11–13].
The advantage of next generation sequencing (NGS) for elucidating the possibility of an oligogenic
inheritance for DSD and other endocrine pathologies has been highlighted [14]. In the present work,
we describe the clinical features of seven 46,XY DSD patients harboring a heterozygous NR5A1 variation.
We performed functional characterization of novel, possibly disease-causing variants. Additionally,
individuals were investigated with a targeted gene panel including 48 DSD genes to search for a second
hit that may contribute to their phenotype [15]. Finding likely disease-causing variants in known DSD
genes in 50% of studied cases suggests that digenic inheritance may explain the variable phenotypic
expression observed in these patients with heterozygous NR5A1 variants.
2. Results
2.1. Clinical Features and Follow-Up
A summary of the clinical and biochemical features of the patients is given in Table 1. Three of the
patients (Cases 1, 3 and 6) who were assigned male sex at birth presented with ambiguous genitalia
(micropenis, hypospadias, bifid scrotum or cryptorchidism). Four patients were reared as females.
Two of them (Cases 4 and 5) were referred at 14 years of age because of primary amenorrhea with
rudimentary uterus and vaginal pouch. Additionally, Case 4 had clitoromegaly. The other two female
patients (Cases 2 and 7) were referred at ages seven and one, respectively, for clitoromegaly and vaginal
pouch. Case 2 also had bilateral inguinal masses.
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Table 1. Clinical and biochemical characteristics of the studied patients.
Case
(Gender)
Phenotype Hormonal Findings
Genital Anatomy, Histology and
Presence of Müllerian Ducts Age 17OHP DHEA-S Androst T DHT FSH LH AMH Others
1 (m)
At birth: curved micropenis, hypospadias,
cryptorchidism. Surgery. At 12 y: penis
7.6 cm. MRI: testis 5 mL, small cysts.
At 15 y: MRI: right testis (3.2 mL) and left
testis (3.3 mL), small cysts. Absence of
Müllerian ducts.
10 y 1.7/1.9 † 86.3/187.4 † 0.19/0.15 † 11.9 0.9
11 y 1.3 2.5 290.5 0.5 30.4 7.1
14 y 1900 412.5 35.9 11.4 <0.1
15 y 2010 4.1 518 0.5 38.9 14.6 0.4
2 (f)
At 10 y: bilateral inguinal hernia and
gonads, clitoromegaly. US: vaginal pouch,
no uterus. Histology: hypoplastic testis.
Gonadectomy. At 20 y: good breast
development after estrogen treatment.
At 25 y: US: prepuberal hypoplastic
uterus. No ovaries. Müllerian ducts.
10 y 1.9 1.0 250 24 95 E2: 16
27 y 0.5 2.5 21.4 8.4 E2: 26.4
3 (m)
At birth: micropenis, hypospadias,
undescended testes. 5 y: normal penis,
right testis 2 mL and hydrocele left testis.
At 6 y: smaller penis, scrotal testes.
Absence of Müllerian ducts.
2 d 202 23.6 1.5 <0.5 <0.5 F: 10.4
1 m 400 67.5 3.7 2.5 F: 6.1
4 (f)
At 14 y: primary amenorrhea, virilization.
clitoromegaly, scrotal rests.
US: rudimentary uterus, atrophic testis in
left inguinal canal. At 15 y: gonadectomy.
Histology: testis with Sertoli cells and
epididymis. Müllerian ducts:
rudimentary uterus.
14 y 0.9 1.61 1.7 193 0.5 112.5 37.8 0.4 E2: 16.7
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Table 1. Cont.
Case
(Gender)
Phenotype Hormonal Findings
Genital Anatomy, Histology and
Presence of Müllerian Ducts Age 17OHP DHEA-S Androst T DHT FSH LH AMH Others
5 (f)
At 14 y: primary amenorrhea, stenotic and
enlarged vagina. At 15 y: laparoscopy:
rudimentary uterus, streak gonads.
Gonadectomy. Histology: testicular
parenchyma, normal fallopian tubes.
Müllerian ducts: vagina,
rudimentary uterus.
14 y 0.5 1960 2.0 36.6/46 † 44.3 12.2 <0.01 F: 18/27 †; E2:31.0
6 (m)
At birth: micropenis, hypospadias,
palpable gonads. At 2 y: biopsy.
Histology: testicular tissue. 17 y: absence
of germ cells and Leydig cells hypoplasia.
At 10 y: penis 2.6 cm. At 14 y:
penis 5.5 cm, scrotal testes. At 17 y:
biopsy. At 38 y: penis 3–4 cm, testes 2 cc.
Absence of Müllerian ducts.
10 y 20/130 †
14 y N 180/350 † 55 15 ACTH: N; F: N
15 y 140/500 † 39/72 † 11/137 †
38 y 0.3 1293 1.4 500 25 15.6 <0.1 ACTH: 36; F: 14.3;E2: 20
7 (f)
At 1 y: hypertrophic clitoris, fused labia
minora. MRI: vagina (3.2 cm) without
annexes. Genitoplasty. At 3 y: US:
absence of ovaries and uterus. Absence of
Müllerian ducts.
1 y 0.4 <17 0.6 8 1.2 0.5 40.3 F: 12.1; E2: <10
7 y 14 3.8 0.05 E2: <11
17OHP, 17-hydroxyprogesterone (ng/mL); ACTH, adrenocorticotropic hormone (pg/mL); AMH, anti-Müllerian hormone (ng/mL); Androst, androstenedione (ng/mL); F, cortisol (ug/dL);
DHEA-s, dehydroepiandrosterone sulphate (ng/mL); DHT, dihydrotestosterone (ng/mL); E2, estradiol (pg/mL); f, female; FSH, follicle-stimulating hormone (U/L); LH, luteinizing hormone
(U/L); m, male; MRI, magnetic resonance imaging; N, normal; T, testosterone (ng/dL); US, ultrasound; y, years. † After human chorionic gonadotropin (hCG) stimulation test. All patients
presented with a 46,XY karyotype. Laboratory test values outside the normal range of age and chromosomal sex are given in bold.
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All three male assigned individuals received surgical repair for their external genital ambiguity
during early infancy. At follow-up, they were supplemented with testosterone, except for Case 1,
who had spontaneous pubertal development. All cases maintained their assigned sex of rearing on
follow-up. The three adult female patients who underwent gonadectomies (Cases 2, 4 and 5) and had
hypoplastic/rudimentary uterus received estrogen replacement therapy.
2.2. Identification of NR5A1 Gene Variants and Other DSD-Related Gene Variants in Patients Presenting with
46,XY DSD
Pathogenic NR5A1 gene variants according to ACMG (American College of Medical Genetics)
standards [16] were identified in all seven patients either by analysis with a targeted gene panel
or by candidate gene sequencing (Table 2). Case 1 carried a novel heterozygous c.88T>A missense
variant in exon 2, leading to a p.Cys30Ser substitution in the loop of the first zinc finger domain of
the protein (Figure 1). Both parents were studied and did not carry the variant, indicating that this
change occurred de novo in the patient. Similarly, gene-by-gene analysis of Case 6 revealed another
missense alteration in this crucial region of NR5A1; the His c.71A>T (p.His24Leu) change had not
been reported before. Case 3 (male) presented with the c.250C>T; p.Arg84Cys NR5A1 variant. Located
in the A box of the DNA binding domain (DBD), this variant has been previously described in a
case of 46,XY DSD [17]. Remarkably, his mother, maternal uncle and aunt suffer from DSD-related
clinical features and were found to be carriers of the same heterozygous NR5A1 variation. However,
the same variant was also found in his healthy brother and grandfather. In Case 2, a frameshift
insertion (c.614_615insC; p.Gln206ThrfsX20) in exon 4 was identified and predicted to produce an early
protein truncation. Further NR5A1 gene variations were detected in the ligand binding domain (LBD)
of the protein (Figure 1). Case 5 and her mother presented the c.902G>A missense variant. Located in
exon 5, this cysteine to tyrosine substitution in codon 301 (p.Cys301Tyr) is novel. Finally, in Case 4,
a four-nucleotide deletion (c.910_913delGAGC) was found and predicted to produce a shorter protein
consisting of 330 amino acids (p.Glu304CysfsX26) instead of 461 as seen with wild-type (WT) NR5A1.
The mother of Case 4 is a carrier of the variation. Sequencing of Case 7 revealed a heterozygous
c.1183_1185delGAG non-frameshift variation in exon 7 that leads to the deletion of amino acid 395
(p.Glu395del) in the LBD of the protein. This variant was also found in the mother of the patient.
Except for Case 4, DNA samples of patients, in which only a single gene approach had been
performed initially, were further analyzed by the targeted DSD gene panel including 48 genes [15].
Additional heterozygous variants in known DSD genes were found in three out of six (50%) 46,XY DSD
NR5A1 carriers. For Case 1, a novel missense VUS (variant of unknown significance) variant (c.361C>T;
p.Arg121Trp) in the STAR gene was identified in the patient and his father. A rare variant in AMH,
c.428C>T; p.Thr143Ile, was detected in Case 2 and was classified as VUS. Finally, for Case 7 and her
father, a previously reported ZFPM2/FOG2 (c.1632G>A; p.Met544Ile) pathogenic missense alteration
was identified [18]. No additional variants in other genes associated with testicular development and
DSD were identified by our panel in Cases 3, 5 and 6. We were not able to further analyze Case 4
because of a lack of sample availability.
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Table 2. Genetic findings of studied patients. Specific variants in NR5A1 and in other disorders of sex development (DSD)-related genes assessed by a DSD-tailored
gene panel are listed [15].
Case Genetic Approach
NR5A1 Gene Variant Second Suspected Gene Variant by NGS Genes Studied by
Sanger (Normal)
Genomic and Protein Change † Familial Studies Gene Variant † andClassification ‡ Familial Studies
1 CGA + TGP c.88T>A; p.Cys30Ser Non-carriers: father,mother, brother
STAR, c.361C>T;
p.Arg121Trp
(rs34908868)/VUS ‡
Carrier:
fatherNon-carriers:
mother, brother
SRD5A2, AR, FMR1
2 CGA + TGP c.614_615insC; p.Gln206ThrfsX20.Ass with 46,XY DSD [7] Non-carrier: mother
AMH, c.428C>T;
p.Thr143Ile. Ass with
PCOS [19]/VUS ‡
Non-carrier: mother AR, HSD17B3
3 TGP c.250C>T; p.Arg84Cys. Ass with46,XY gonadal dysgenesis [17]
Carriers: mother, uncle,
aunt, grandfather, brother.
Non-carriers: father, sister,
grandmother
Further studies needed No
4 CGA c.910_913delGAGC;p.Glu304CysfsX26
Carrier: mother.
Non-carrier: sister ND SRY, AR
5 CGA + TGP c.902G>A; p.Cys301Tyr
Carrier: mother
(mosaicism). Non-carriers:
father, brother
Further studies needed SRY, HSD17B3
6 CGA + TGP c.71A>T; p.His24Leu ND Further studies needed AR
7 TGP c.1183_1185delGAG; p.Glu395del Carrier: mother.Non-carrier: father
ZFPM2, c.1632G>A;
p.Met544Ile. Ass with
46,XY DSD [18]/LP ‡
Carrier:
fatherNon-carrier:
mother
No
Ass, associated; CGA, candidate gene approach; LP, likely pathogenic; ND, not determined; PCOS, polycystic ovary syndrome; TGP, targeted gene panel; VUS, variant of unknown
significance. † If mutation has been previously reported, reference is indicated; ‡ According to ACMG (American College of Medical Genetics) standards [16]. Sequence information is
based on the following reference sequences: NR5A1: NM_004959; STAR: NM_000349; AMH: NM_00479 and ZFPM2: NM_012082. All variants were present in heterozygous form.
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All three novel NR5A1 variants had significantly reduced activity on the CYP17A1 reporter 
compared to WT (Figure 2A). These results were confirmed for the His24Leu and Cys30Ser variants 
when using the reporters for CYP11A1 and HSD17B3 (Figure 2B,C). In contrast, variant Cys301Tyr 
did not change the reporter activities of CYP11A1 and HSD17B3 (Figures 2B,C). 
Expression of NR5A1 variants was assessed by Western blot in our cell model. As shown in 
Figure 2D, SF1 protein expression was similar for all studied NR5A1 variants. 
Figure 1. Sche e of the structure of the NR5A1 protein and localization of studied variations. Critical
functional domains comprise a DNA-binding domain (DBD) at the amino terminal (from amino acids
13 to 112) containing two zinc finger domains (ZNI and ZNII) and an A box, the flexible hinge region
(amino acids 112–225) and a ligand-binding domain (LBD) (amino acids 225–458) with activation
function 1 (AF1) and 2 (AF2). A close-up loop of the first zinc finger domain in DBD is shown where
the His24Leu and Cys30Ser alterations are located. Locations of the NR5A1 variations described in this
work are indicated by arrow heads.
2.3. Transcription Activity and Protein Expression Testing of Novel NR5A1 Variants
To study the impact of the three novel missense variants of NR5A1 on transactivation activity
of regulated genes, HEK293 cells were co-transfected with WT or mutant NR5A1 expression vectors
and three different promoter reporter constructs essential for steroid and sex hormone biosynthesis.
All three novel NR5A1 variants had significantly reduced activity on the CYP17A1 reporter compared
to WT (Figure 2A). These results were confirmed for the His24Leu and Cys30Ser variants when using
the reporters for CYP11A1 and HSD17B3 (Figure 2B,C). In contrast, variant Cys301Tyr did not change
the reporter activities of CYP11A1 and HSD17B3 (Figure 2B,C).
Expression of NR5A1 variants was assessed by Western blot in our cell model. As shown in
Figure 2D, SF1 protein expression was similar for all studied NR5A1 variants.
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duplicate. (D) Western blot showing expression of WT and mutant NR5A1/SF1 proteins. The HA 
antibody recognized hemagglutinin-tagged NR5A1/SF1 (band at 53 kDa). β-actin was used as a 
control (band at 42 kDa). ** p-value  ≤  0.01. HA, hemagglutinin; RLU, relative light units; Ve, empty 
vector; WT, wild type. 
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clinical spectrum (Table 1). Three patients manifested at birth as undervirilized males with 
ambiguous genitalia and four presented with typical female external genitalia. They mostly had 
adequate testosterone production and good or even high response to hCG stimulation tests, even 
enough to induce pubertal development in some of them. According to the literature, variable 
hormonal findings are found in persons with NR5A1 variants and do not correlate with the 
phenotype of the external genitalia [2]. Normal testosterone concentrations, at least in early 
childhood, have been found in NR5A1 variant patients with cryptorchidism, hypospadias and 
micropenis [7,20], as well as in 46,XY subjects presenting with a female phenotype [21,22]. In contrast, 
testosterone synthesis might not be sufficient to start or proceed through puberty. This may be 
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Figure 2. Functional studies of the three novel NR5A1 variants. The ability of wild-type (WT) and
mutant NR5A1 to activate promoter luciferase reporter constructs was tested in HEK293 cells (A–C).
Cells were transiently transfected with NR5A1 expression vectors and promoter reporter constructs:
227CYP17A1_∆luc (A), -301HSD17B3_pGL3 (B) and -152CYP11A1_pGL3 (C) [7]. Results are shown
as the mean ± standard error of the mean (SEM) of five independent experiments, all performed in
duplicate. (D) Western blot showing expression of WT and mutant NR5A1/SF1 proteins. The HA
antibody recognized hemagglutinin-tagged NR5A1/SF1 (band at 53 kDa). β-actin was used as a control
(band at 42 kDa). ** p-value ≤ 0.01. HA, hemagglutinin; RLU, relative light units; Ve, empty vector;
WT, wild type.
3.
ti t r i ri t if it e tre l broa phenot s, ra i fro
or al sex development o complete s x reversal. A lack of genotype–phenotype correlation has been
widely qu stioned, a d the hypothesis f additional genetic varia ons contributing to the complex
and variable phenotype has been formulated [2,8,10,13]. In this work, we report clinical and genetic
data of seven 46,XY DSD patients wi h heterozygous NR5A1 variants with normal adrenal function.
Using targeted ene panel analysis for sex devel pment-related g es, we found a second likely disease
causing/pathogenic vari nt in known DSD genes (STAR, AMH, ZFPM2) in three of six studied 46,XY
DSD individuals, support ng the hypothesis of oligogenic disease.
r often found in 46,XY DSD individuals. Th ir external genital phenotype
m y vary from typical male with infer ility to hypospadias or ambiguous genitalia, t fe ale
e t r l e t it pri ar a enorrhea [2]. i e
clinical spectrum (Table 1). Three patients manifested at birth as undervirilize males with ambiguous
genitalia and four presented with typical female external genitalia. They mostly had adequate
testosteron production and go d or even high response to hCG timulation ests, eve enough to
induce pubertal development in some of them. According to the literature, variable ho monal findings
are fou d in persons with NR5A1 variants and do not correlate with the phenotype of the ex ernal
genitalia [2]. Normal stosterone concentrations, a least in early childhood, have b en found in
NR5A1 variant pati nts with cryptorchidism, hypospadias and mi o enis [7,20], as well as in 46,XY
subjects presenting with a female phenotype [21,22]. I con rast, testostero e synthesis might ot be
Int. J. Mol. Sci. 2020, 21, 8554 9 of 18
sufficient to start or proceed through puberty. This may be explained by a progressive replacement of
the differentiated normal testicular tissue with connective tissue over time, followed by the loss of
seminiferous tubules, finally leading to the absence of gonadal tissue in adulthood [7]. As expected,
the two male patients (Cases 3 and 6) with normal hCG stimulation tests in early childhood needed
testosterone supplementation for pubertal development. Interestingly, Case 1 achieved spontaneous
pubertal development, and the female patients presented with signs of (progressive) virilization at
different ages. Virilization [23] or spontaneous pubertal development [2] have been described in 46,XY
DSD individuals with a NR5A1 variant, even with elevated gonadotropin levels [7], indicating that the
Sertoli cell damage might be more severe than the damage to the Leydig cells [21]. Our 46,XY DSD
cases had generally low AMH levels, which might explain why the three female assigned persons
had a rudimentary developed uterus, and fallopian tubes were only found in one. However, similar
to previous cases [20,21,24], no Müllerian structures were found in the other four studied cases (one
female, three males) despite only low AMH. This might be explained by the prominent action of AMH
in utero, and with progressive malfunction of the AMH-producing Sertoli cells with age, evidenced by
the gradually increasing FSH with low LH/FSH ratio [21,24]. None of our patients had symptoms of
adrenal insufficiency so far. Although adrenal insufficiency is a rare finding in individuals with NR5A1
variants [6], adrenal function should be followed regularly as life-threatening adrenal insufficiency
may develop later in life [2].
Huge phenotypical variability has also been observed within families carrying NR5A1
variants [7,25]. We confirmed NR5A1 variant transmission from one of the parents in four of six
cases. In two cases, no carriers were found (Table 2). Family history of one of our index patients
revealed premature menopause, menstrual disorders and isolated hypospadias in three relatives
harboring the same p.Arg84Cys NR5A1 variation. In 46,XX individuals, NR5A1 variants are associated
with primary ovarian insufficiency [7,26], and most of these women have relatives with a 46,XY DSD [27].
Similarly, NR5A1 sequence variants have been described in males with isolated hypospadias [28].
The majority of reported NR5A1 variants are maternally inherited or occurred de novo [29]. Four of
our studied cases (Cases 3, 4, 5 and 7) showed maternal inheritance. In the two cases where variant
inheritance was not proven, only one of the parents was available for testing for one case (Case 2);
thus we cannot determine whether the p.Gln206ThrfsX20 variant occurred de novo, although the
exactly same variation has been described [7]. Healthy carriers with heterozygous variants in NR5A1
have been reported [7].
Previously reported NR5A1 variants were mostly non-synonymous and were mainly located in
the DBD of the protein [6]. We detected two novel variants in the first zinc finger of the DBD (His24Leu,
Cys30Ser) that manifested with undervirilized ambiguous male genitalia at birth and with elevated
gonadotropins and small testes later. In addition, one case (Case 6) needed androgen replacement early
in life and was proven to have Leydig cell hypoplasia. Camats et al. [7] described other amino acid
changes in these codons (His24Tyr and Cys30Trp) in 46,XY DSD females with an inguinal hernia and
abnormal testicular tissue. The highly conserved residues in these domains are essential for DNA and
zinc binding (Cys30), and genetic alterations probably interfere with binding and inhibit transcriptional
activation, resulting in variable loss of NR5A1 function. A third variant (Arg84Cys), identified in one of
our cases, was located in the A-box of the DBD crucial for DNA anchoring. This pathogenic variant has
been described in 46,XY males with similar phenotypes [17,30], but also in a 46,XY female with adrenal
insufficiency [31], which confirms the clinical divergence of a single genotype with NR5A1 DSD. Case 2
carried the reported Gln206ThrfsX20 variant in the hinge region of the protein, predicted to produce
an early truncation and ineffective NR5A1 protein. The prior reported patient with this frameshift
variation had similar clinical features, except for the hypoplastic uterus [7]. The hinge region of NR5A1,
besides connecting the LBD and the DBD, is important for protein configuration and is a target for post
translational modifications, such as phosphorylation, which has been demonstrated to promote NR5A1
stability and transcriptional activity [32]. The LBD is responsible for modulating NR5A1 activity
through bond formation between its AF2 domain and phospholipid ligands [33]. We identified three
Int. J. Mol. Sci. 2020, 21, 8554 10 of 18
novel NR5A1 variants in the LBD in female phenotypic 46,XY DSD cases. Two variants are predicted
to produce truncated proteins (Glu304CysfsX26 and Glu395del) and one a missense Cys301Tyr protein.
While our 46,XY cases with NR5A1 variations in the LBD presented with a predominant female
phenotype, others have reported cases with variants in same and similar location with a rather male
typical phenotype, e.g., hypospadias and anorchia [34,35].
When tested for promoter transactivation activity in HEK293 cells, we found that the two NR5A1
variants located in the DBD showed consistently impaired activity, while Cys301Tyr, located in the
LBD, demonstrated variable results with different promoters, and therefore its pathogenicity may be
questioned. Similarly inconsistent results have been reported for other variants [2,7,21].
Possible digenic or oligogenic inheritance of genetic disorders of sex development with a broad
phenotype has been discussed by us [8,14,36] and others [2,10–13,37,38]. We therefore searched for
additional gene variants in the studied cases and found a second genetic variant in a gene previously
reported to be involved in male sex development [6] in three individuals (Table 2). In two cases
(Cases 2 and 3), NGS analysis revealed missense monoallelic variants in the STAR (OMIM 600617)
and AMH (OMIM 600957) genes, respectively. Although the identified Arg121Trp STAR variant
was defined as pathogenic by most prediction tools, no STAR variant has been described with an
isolated DSD phenotype so far, and with a disease phenotype at all in heterozygote carriers. In
contrast, mild autosomal recessive, non-classic STAR genetic alterations may cause isolated adrenal
insufficiency [39]. Thus, the Arg121Trp STAR variation must be categorized to be of unknown
significance (VUS). Interestingly, the same heterozygous STAR variant was found in the healthy
father, who is not carrying the NR5A1 variant (shared by the mother), suggesting that only the
combination of both gene variants may lead to the observed phenotype. Certainly, it is advisable to
follow this patient closely for the development of adrenal insufficiency. Concerning the rare variant
in the AMH gene identified in Case 2, it has been previously described in a female with polycystic
ovary syndrome, as well as in a control population [19]. Finally, the female Case 7 and her father
carried a heterozygous FOG2/ZFPM2 missense variation (OMIM 603693). Similar to the previously
reported cases by Bashamboo et al. [18], our patient presented with 46,XY gonadal dysgenesis, no
heart anomalies, and had genetically positive relatives who were asymptomatic. The potential role of
heterozygote variations in the ZFPM2 gene might therefore only be relevant in combination with a
variation in another DSD-related gene.
It is well known that both STAR and AMH genes are regulated by NR5A1 [6,40]. The nuclear
receptor NR5A1/SF1 is expressed in the bipotential gonad, and modulates genes like SRY and SOX9 to
regulate and maintain male determination [41]. In Sertoli cells, NR5A1/SF1 enables the expression
of AMH and its receptor AMHR2, which are essential for the regression of the paramesonephric
ducts [42]. NR5A1/SF1 also regulates the expression of genes essential for steroidogenesis, such as
STAR and CYP17A1 in Leydig cells, which are required for testosterone biosynthesis and virilization
of the fetus [33]. The zinc finger protein ZFPM2 (or FOG2, Friend of Gata) interacts with GATA4 to
modulate its transcriptional activity. Formation of heterodimers together with NR5A1/SF1 is thought
to be necessary for proper cell differentiation in the testis [43], and has been demonstrated to regulate
the expression of Sry, Sox9 and Amh in mice [44–46]. Although initially described in patients with
cardiac anomalies only [47], recent studies have illustrated that haploinsufficiency and variants of the
ZFPM2/FOG2 gene may cause 46,XY gonadal dysgenesis [43]. Furthermore, the ZFPM2/FOG2 variant
Met544Ile showed impaired interaction with GATA4 [18]. More recently, all previously described
variants of ZFPM2/FOG2 were revaluated and classified as benign due to their allelic frequencies and
transactivation activity similar to WT [48]. Therefore, we and others [8] suggest that heterozygous
ZFPM2/FOG2 variants may not be pathogenic by themselves, but contribute to a DSD phenotype when
occurring in combination with heterozygous NR5A1 variants (or in combination with variants of other
DSD-related genes). With this hypothesis in mind, the normal phenotype of the fathers of Cases 1 and
7 compared to their offspring can be explained by the presence of variants in more than one gene in the
patients, producing a cumulative pathogenic effect.
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DSD is caused by a large group of genetic conditions and the discovery of underlying genes
is constantly expanding through the use of NGS technologies. In this study, we have characterized
seven patients harboring novel and known heterozygous NR5A1 variants and thereby increased the
number of known NR5A1 variants. Using a DSD targeted gene panel, we found additional variants
in STAR, AMH and ZFPM2 in three of the six studied individuals with variable DSD phenotypes.
This clearly supports the hypothesis that the broad clinical spectrum seen with NR5A1 variants is
due to di-/oligogenic causation. Overall, the genetics underlying DSD might be more complex than
initially thought. Variable phenotypes and lack of a genotype–phenotype correlation hint at a complex
network of genes and modifiers working together. The use of NGS offers the opportunity to explore
this complex network. However, to understand the role of each participating gene and the mechanistic
connections remains challenging. Therefore, in future work we plan to study the specific role of
identified genes involved in this network using induced steroidogenic cells reprogrammed from
patient fibroblasts carrying the genetic signature of the individual patient. Basic protocols for this
novel approach to perform mechanistic studies and move towards cell based therapies have been
published recently [49–51].
4. Materials and Methods
4.1. Patients and Samples
The seven patients with 46,XY DSD included in this study are part of a larger cohort recruited at
the Biocruces Bizkaia Health Research Institute (Barakaldo, Spain). Clinical data were provided by
the responsible clinicians and a written informed consent was obtained from all participants or their
parents. The study was approved by Swiss ethics (BASEC 2016-01210, date: 5.11.2017) and informed
by the local ethical committees, namely the ethical boards of the Regional University Hospital Malaga,
Spain, Ramon y Cajal University Hospital, Madrid, Spain, Manises Hospital, Manises, Spain, Nuestra
Señora de Candelaria University Hospital, and Santa Cruz de Tenerife, Spain, as well as the ethics
committee for clinical research of Euskadi (CEIC-E), Spain. Additional studies on this cohort have
been reported elsewhere [52].
4.2. Case Reports
A summary of the clinical and biochemical characteristics of the seven studied patients is given in
Table 1.
Case 1: This newborn was noted at birth to have curved micropenis, chordee with scrotal
hypospadias and bilateral cryptorchidism. Surgical correction was performed. Karyotype was 46,XY.
At 10 years of age, stimulation test with human chorionic gonadotropin (hCG) resulted in a normal rise
of testosterone (187.4 ng/dL). At 12 years of age, his penis was 7.6 cm in size, and testes nearly 5 mL.
MRI showed testes of 3.2 mL and 3.3 mL. Cysts of 6.4 mm and 2.7 mm were observed in the right and
left epididymis, respectively. Asperger syndrome was suspected at the age of 13 years old, but the
genetic study of the FMR1 gene was normal. At 14 years of age, biochemical analysis revealed elevated
serum levels of gonadotropins (LH 11.4 U/L, FSH 35.9 U/L) and a testosterone level of 412.5 ng/dL with
low levels for AMH (<0.1 ng/mL). At a recent follow-up at 15 years of age, penile size is still in the
normal limit with high levels of LH and FSH with a testosterone level of 518 ng/dL. Family history is
remarkable for unilateral renal agenesis in the mother as well as in a brother, who also has vas deferens
and left epididymis agenesis.
Case 2: This female was referred at 10 years of age because of clitoromegaly, bilateral inguinal
masses and accelerated growth. She presented with early pubarche and facial hair growth. Karyotype
was 46,XY. Pelvic ultrasound showed a vaginal pouch and absent uterus. Palpable gonads were located
at the inguinal canal (2 and 3 mL). Biochemical analysis was remarkable with elevated gonadotropins
and a testosterone of 250 ng/dL. Gonadectomy and histology revealed two testes of 2.4 and 2.5 cm with
germ cell hypoplasia. Oral estrogen therapy was initiated and replaced by transdermal supplementation
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after 9 years. This resulted in good breast development, although regression was observed when the
dose was decreased. During the following years, reconstructive surgery was performed, achieving
a permeable vagina of 2–3 cm and a normal clitoris. Abdominal ultrasound showed a normal bladder
and a small structure (26 mm) above the urethra, hinting at a possible prepuberal hypoplastic uterus.
No ovaries were visualized. At 27 years of age, the patient was well developed. Hormonal values were
in the normal, age- and sex-appropriate range under supplementation therapy (LH, E2). FSH remained
elevated after gonadectomy.
Case 3: This patient presented with micropenis, scrotal hypospadias, undescended testes, and bifid
scrotum at birth. Karyotype was 46,XY. Abdominal ultrasound revealed no anomalies. Biochemically,
LH and FSH were normal (2.5 and 3.7 U/L, respectively) with a low testosterone of 67.5 ng/dL in the
first month of life. At 3 months of age, four doses of testosterone were prescribed (50 mg/dose) with
adequate penile response. When he was 4 years old, he had hypospadias repair surgery. At 5 years of
age, physical examination showed a penis of 2.5 cm in size, right testis of 2 mL and a hydrocele of
the left scrotal compartment. At 6 years of age, replacement therapy with testosterone was started.
Penile length increased to 3 cm and pubic hair was noted. Interestingly, his mother presented with
premature menopause, the maternal uncle presented with scrotal hypospadias at birth, and his aunt
presented with menstrual disorders.
Case 4: This female was seen at 14 years of age because of virilization during puberty and primary
amenorrhea. Pubarche and axilarche had started at 8 years of age. The patient presented with typical
female genitalia at birth. Physical exam revealed a female clinical phenotype with excessive facial and
body hair and lack of thelarche. Clitoris with perineal-located urethra were noted. There were no
inguinal masses. Karyotype was 46,XY. Abdominal and pelvic MRI showed a rudimentary uterus,
and a computerized axial tomography (CAT) scan showed a small uterus and atrophic gonads in the
left inguinal canal. Laboratory analysis showed elevated LH and FSH levels (37.8 U/L and 113 U/L
respectively) with high levels of testosterone for a female (193 ng/dL). Antiandrogens were prescribed
(50 mg/day). At 15 years of age, gonadectomy was performed. Histology revealed fibro-adipose
and skeletal muscle tissue together with a testis of Sertoli-cell only phenotype and well identified
epididymis. After surgery, estrogen patches were added to the pharmacological treatment.
Case 5: This patient presented with primary amenorrhea and obesity at 14 years of age. She had
a stenotic and enlarged vagina, which was possibly a vaginal pouch. Karyotype was 46,XY. Abdominal
and pelvic ultrasound and MRI demonstrated a rudimentary uterus and vagina, but neither testes nor
ovaries were identified. Biochemical analysis at this time showed increased levels of gonadotropins
with a testosterone level of 36.6 ng/dL only. Stimulation test with hCG resulted in an insufficient rise of
testosterone (47.70 and 46.0 ng/dL for the third and fifth dose of hCG, respectively). Laparoscopy at
15 years of age revealed a rudimentary uterus and streak gonads. Gonadectomy and biopsy showed
gonadal tissue compatible with non-functioning testicular parenchyma and normal fallopian tubes.
Family history was unremarkable.
Case 6: This patient was noted at birth to have curved penis buried in mons pubis, perineal
hypospadias, bifid scrotum and palpable gonads. His karyotype was 46,XY. At 2 years of age, biopsy
showed testicular tissue without alterations, and laparoscopy did not find Müllerian remnants. During
the following years, hypospadias was corrected. At 10 years of age, penile length was 2.6 cm, right testis
was located in scrotum and the left was inguinal. Stimulation test with hCG resulted in a normal
rise of testosterone. He started treatment for micropenis with topical application of testosterone,
which increased phallic size to 3.5 cm and initiated pubarche. At 14 years of age, the boy had a penile
length of 5.5 cm and testicular volume of 2–3 mL bilaterally. Biochemically, gonadotropins were elevated
(LH 15 U/L; FSH 55 U/L) and testosterone low (1.8 ng/dL). ACTH, cortisol and 17-hydroxyprogesterone
were within the normal range. Bone age was similar to chronological age. Intramuscular testosterone
treatment was prescribed again (125 mg/3 weeks) for 6 months. At 15 years of age, penile length was
7 cm and testes were still only 2 mL in volume. Testosterone treatment was stopped for 2 months and
LHRH stimulation test revealed a normal response of gonadotropins and testosterone (Table 1). In the
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following years, orchidopexy was performed, and a second biopsy revealed the absence of germ cells,
and Leydig cels hypoplasia. Thus, testosterone supplementation treatment was restored, but stopped
again shortly after by the patient because of widespread edema. Currently, the patient has a penile
length of 3–4 cm and bilateral testicular volume of 2 mL. LH and FSH are elevated and testosterone is
low (500 ng/dL). The patient also suffers from obesity (BMI: 42 kg/m2).
Case 7: This 1-year-old female was referred to paediatric surgery for clitoromegaly and fused
labia minora. At that time, ultrasound was not conclusive and abdominal and pelvic MRI showed
a small vagina (3.2 cm) without fallopian tubes. Karyotype was 46,XY. Basal hormonal testing indicated
slightly reduced FSH (1.23 U/L) while LH was elevated (0.56 U/L). Testosterone levels were in the
normal female range, and AMH was increased (40.3 ng/mL). After stimulation with hCG, testosterone
increased highly (8.0 ng/dL), while DHEA-S levels remained in the normal range for age and female
sex. During genitoplasty, the absence of a uterus and ovaries was confirmed. When the patient was
3 years old, a structure of 3 cm was seen by ultrasound, most likely corresponding to a vaginal pouch.
Recent laboratory results at 7 years of age showed normal values for age and sex (Table 1).
4.3. Genetic Testing
Extraction of DNA from peripheral blood leukocytes was performed using either the MagPurix
Blood DNA Extraction Kit 200 (Zinexts Life Science Corp., New Taipei City, Taiwan) or the QIAamp
DNA Blood Minikit (Qiagen, Venlo, Netherlands).
4.4. Design of the Targeted Gene Panel and Screening via Next-Generation Sequencing
A targeted gene panel (TGP) was designed to include 48 genes associated with DSDs in online
databases, including PubMed (https://www.ncbi.nlm.nih.gov/pubmed/), Human Gene Mutation
Database (HGMD, https://portal.biobase-international.com) and Online Mendelian Inheritance in
Man (OMIM, https://www.ncbi.nlm.nih.gov/omim) [15]. Libraries were prepared according to the
manufacturer’s instructions and samples were sequenced using the Ion PGM platform (Thermo Fisher
Scientific, Waltham, MA, USA). Base calling, read filtering, alignment to the reference human genome
GRCh37/hg19, and variant calling were done using Ion Torrent Suites (Thermo Fisher Scientific,
Waltham, MA, USA). Further QC analysis, coverage analysis and variant filtering were completed with
the Ion Reporter Software (Thermo Fisher Scientific, Waltham, MA, USA). Coverage depth and read
quality were evaluated with the Integrative Genomics Viewer (IGV, broadinstitute.org, Cambridge,
MA, USA). Variants were filtered to include only those with a Phred-like score ≥ 30, p-value < 0.001,
and minor allele frequency (MAF) < 1%. Variants found in the TGP were confirmed via amplification
of the exons by PCR and sequencing. When available, DNA samples from the patients’ relatives were
screened likewise.
4.5. Sequencing of the Coding Sequence of NR5A1
The coding exons of NR5A1 were amplified by PCR and analyzed by bidirectional direct sequencing
using the BigDye Terminator v3.1 Cycle Sequencing Kit (Thermo Fisher Scientific, Waltham, MA, USA)
in an ABI 3130xl DNA Genetic Analyzer (Thermo Fisher Scientific, primer sequences and conditions
are available from the authors, on request). All variants were annotated according to the GenBank
reference sequences NM_004959 and NP_004950.
4.6. In Silico Analyses and Variant Classification
We used the following online tools to predict the impact of the non-synonymous alterations on
protein function: PROVEAN (Protein Variation Effect Analyzer) (http://provean.jcvi.org/index.php),
SIFT (Sorting Intolerant From Tolerant) (http://sift.jcvi.org/), Polyphen 2 (http://genetics.bwh.harvard.
edu/pph2/), Mutation Taster (http://www.mutationtaster.org/), SNPs and Go (http://snps.biofold.
org/snps-and-go/snps-and-go.html), MutPred (http://mutpred.mutdb.org/), Panther (http://www.
pantherdb.org/) and Varsome (https://varsome.com/). Variants were classified following the standards
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and guidelines from the American College of Medical Genetics and Genomics (ACMG) [16]. Previously
reported clinical associations were searched in the databases ClinVar (https://www.ncbi.nlm.nih.gov/
clinvar) and HGMD.
4.7. In Vitro Transactivation Assays and Protein Expression Analysis
Non-steroidogenic human embryonic kidney HEK293 cells (ATCC CRL-1573) were cultured
and used for functional assays with promoter luciferase reporter vectors –227CYP17A1_∆luc,
–152CYP11A1_pGL3 and –301HSD3B2_pGL3 as previously described [7,53]. NR5A1 expression vectors
containing the novel c.88A, c.902A or c.71T variants were generated by site-directed mutagenesis using
specific primers and the QuickChange protocol by Stratagene (Agilent technologies Inc., Santa Clara,
CA, USA). Results are shown as the mean ± SEM of five independent experiments, performed
in duplicate. Data were statistically analyzed using the Student’s t test. A p-value ≤ 0.05 was
considered significant.
Expression level of WT and mutant SF1 proteins in HEK293 cells after transfection was assessed
by Western blot analysis of cell lysates with an antibody against HA-tag (Merck KGaA, Darmstadt,
Germany). Expression of β-actin protein was used as control.
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HGMD. Human Gene Mutation Database
KO Knockout
LBD Ligand binding domain
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LHRH Luteinizing hormone releasing hormone
LP Likely pathogenic
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